Does modern active surveillance offer an opportunity for new therapeutic strategies in early prostate cancer?

Abstract

National and international guidelines endorse AS as the preferred method of managing men with low-risk disease and as an option for selected men with intermediate-risk features (1). For this latter group there remains understandable anxiety on the part of many clinicians in pursuing a non-interventional approach. This is both a limitation and also a potential opportunity for AS practice to evolve, particularly in the light of modern monitoring tools and a better understanding of prognosis (2).